Skip to main content

Advancing Infectious Disease Testing

Infectious Disease

In the realm of healthcare, infectious diseases pose significant challenges worldwide. The ability to accurately diagnose and monitor infectious diseases is crucial for effective patient management and public health interventions. Viracor, a leading infectious disease testing laboratory, has been at the forefront of innovation, continuously advancing testing capabilities to provide reliable and comprehensive solutions. In this post, we will explore Viracor's commitment to innovation in infectious disease testing and highlight some of their cutting-edge assays.


A Legacy of Excellence:

Viracor has a strong legacy of excellence in infectious disease testing. With over 40 years of experience, Viracor has established a reputation for delivering accurate and timely results, supporting healthcare providers in diagnosing and managing complex infectious diseases.


Innovation Driving Breakthroughs:

To meet the evolving challenges posed by infectious diseases, Viracor consistently invests in the research and development of new assays and testing methodologies. By staying at the forefront of scientific advancements, healthcare professionals are empowered with the most comprehensive diagnostic tools available.


Introducing New Assays:

Viracor's commitment to innovation is evident in their portfolio of new infectious disease assays, which leverage cutting-edge technologies and scientific breakthroughs. Here are a few notable examples:


Next-Generation Sequencing (NGS) Panels:

Viracor is actively developing NGS technology to offer comprehensive infectious disease panels. These panels will screen for multiple pathogens simultaneously, enabling rapid and accurate identification of viral, bacterial, and fungal infections. NGS panels provide detailed genetic information, aiding in the identification, detection of drug resistance, strain typing, and outbreak investigations.


Viral Load Monitoring:

Accurate viral load monitoring is vital for assessing treatment efficacy and guiding therapeutic decisions. Viracor offers highly sensitive viral load monitoring assays, utilizing quantitative PCR methodologies. These assays enable precise measurement of viral replication, assisting healthcare providers in optimizing antiviral therapies and managing patient care.


Multiplex PCR:

Viracor's multiplex PCR assays allow for the simultaneous detection of multiple pathogens in a single specimen. Multiplex PCR streamlines the diagnostic process, reducing turnaround time and conserving valuable patient samples. These assays are particularly valuable in outbreak situations, where rapid identification of the causative agent is critical.


Serological Assays:

Serological assays play a crucial role in identifying past and current infections, assessing immune response, and monitoring vaccine effectiveness. Viracor offers a wide range of serological assays, including antibody detection assays and neutralization assays, all providing valuable insights into immunity against infectious diseases.


Collaborations and Partnerships:

Through collaborations with leading academic institutions, research organizations, and industry partners, Viracor is able to drive innovation in infectious disease testing. Leveraging collective expertise and resources to develop novel assays and validate emerging technologies. This collaborative approach ensures that Viracor remains at the forefront of technological advancements in infectious disease diagnostics.


Innovative Solutions for Better Patient Care

Viracor's unwavering commitment to innovation has positioned it as a leader in infectious disease testing. With continuous investment in research and development, Viracor has pioneered a range of cutting-edge assays that enable healthcare providers with accurate and timely diagnostic information.

The portfolio of innovative assays includes the development of Next-Generation Sequencing (NGS) panels, multiplex PCR assays, and a comprehensive range of serological assays, including antibody detection and neutralization assays, all providing valuable insights for optimal medical care.

Through collaborative partnerships with renowned academic institutions, research organizations, and industry experts, Viracor remains at the forefront of technological advancements in infectious disease diagnostics.

Viracor's dedication to innovation and the development of novel assays empower healthcare providers with the tools they need to accurately diagnose and manage infectious diseases. By advancing infectious disease testing, Viracor plays a crucial role in improving patient outcomes and supporting effective public health interventions.



About the author


Back to top